Cullinan Therapeutics
NASDAQ: CGEMIncorporated in Delaware · 4 known investors
Find your way into Cullinan Therapeutics
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.
Founders & leadership
MK
Mary Kay FentoninChief Financial OfficerMary Kay Fenton is Chief Financial Officer at Cullinan Therapeutics, a clinical-stage biotech company developing therapeutics for autoimmune diseases and cancer. She brings experience in capital formation across venture, mezzanine, and public markets, as well as expertise in strategic transactions, financial reporting, and Sarbanes-Oxley compliance, with prior roles at Big Four firms and an MBA and CPA.
JJ
Jeffrey JonesChief Medical Officer
JM
Jennifer MichaelsoninChief Scientific OfficerJennifer Michaelson is Chief Scientific Officer at Cullinan Therapeutics, a clinical-stage biotech company developing therapeutics for autoimmune diseases and cancer. She has over 20 years of experience in drug discovery and development across oncology, immunology, and immuno-oncology, including portfolio management through IND applications and early clinical development, and has contributed to multiple biotech company fundraising rounds and published over 50 peer-reviewed papers.
CS
Corinne SavillinChief Business OfficerShe holds a PhD in Immunology from the University of London and has worked in business development roles across the biotech and pharmaceutical industries, with experience in oncology and international business development.
JS
Jacquelyn SumerinChief Legal Officer, Corporate Secretary, Chief Compliance Officer
NA
Nadim AhmedinPresident and CEONadim Ahmed is President and CEO of Cullinan Therapeutics, a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer through immune modulation.
Investors · 4
Valuation · disclosed
Disclosed events$876.1Mvaluation at IPOJan 2021 · $21.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlapKite Pharma53 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
C4 Therapeutics41 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Companies competing with Cullinan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Acquisitions · 1
Early investors' stakes continue via these dealsPDI Therapeutics
Developed a first-in-class monoclonal antibody for multiple cancers; acquired by Cullinan Therapeutics in 2022.
In the news
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - Simply Wall St Newssimplywall.st · Aug 2026Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In? - Simply Wall St Newssimplywall.st · Aug 2026
Cullinan Therapeutics 3Q 2026: Revenue $0 Net loss $53.7M, EPS $(0.81) — 10-Q Summarytradingview.com · Aug 2026Frequently asked questions
- What does Cullinan Therapeutics do?
- Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation. The company focuses on first- or best-in-class treatments to improve outcomes for patients managing these conditions.
- Who are Cullinan Therapeutics's investors?
- Cullinan Therapeutics's investors include Foresite Capital, Nextech Invest, Biotechnology Value Fund, OrbiMed.